ClinicalTrials.gg
CompletedNCT03697603Updated Aug 9, 2024Results posted

A Study of Brexpiprazole in Patients With Major Depressive Disorder

A Phase 2/3 interventional study of Brexpiprazole and Placebo in Major Depressive Disorder, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years to 64 Years. Per ClinicalTrials.gov, last updated 2024-08-09.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
740
Allocation
Randomized
Ages
20 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing brexpiprazole in Depressive Disorder, Major — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Depressive Disorder, Major.

Enrollment
10th of 24
740 · median 189
Started
2018
with 3 others
Phase 2/3
Only one
of the 24
Registered
19th of 24
by date
Lead sponsor
2 of 24
Otsuka Pharmaceutical Co., Ltd.

Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, this one is the 10th largest by enrollment, is one of 4 that started in 2018, is the only one in phase 2/3, and was the 19th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 24 studies testing brexpiprazole in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 20 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing brexpiprazole in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of this 14 week, randomized, double-blind, placebo controlled study is to assess the safety and efficacy of brexipiprazole to placebo as adjunctive treatment to an assigned open-label marketed antidepressant therapy (ADT) in patients with Major Depressive Disorder.

03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
20 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Outpatients, or inpatients at the time of whose treatment status can be successfully shifted to outpatient status before enrollment in the antidepressant treatment period
  • Male and female patients ≥ 20 to \< 65 years of age (at the time of informed consent)
  • Patients who have a level of comprehension sufficient to allow them to give written informed consent to all of the observation/examination/evaluation items specified in the protocol, and who can understand the contents of the trial
  • Patients with a classification-based diagnosis of "major depressive disorder, single episode" or "major depressive disorder, recurrent episode," and whose current episode has persisted for at least 8 weeks

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or breastfeeding or who have positive pregnancy test (urine) results at screening
  • Sexually active male subjects or sexually active female subjects of , who will not agree to practice 2 different methods of or to remain abstinent during the trial and for 30 days after the final

IMP administration. For birth control, 2 of the following methods must be used:

vasectomy, tubal ligation, vaginal diaphragm, intra-uterine contraceptive device (IUD), oral contraceptives, or condom with spermicide.

  • Patients with a treatment history showing that all antidepressants (including those not used for the current major depressive episode) cannot be tolerated
  • Patients with a history of electroconvulsive therapy
  • Patients with a diagnosis of any of the following diseases according to

    1. Neurocognitive disorders
    2. Schizophrenia spectrum and other psychotic disorders
    3. Bipolar and related disorders
    4. Feeding and eating disorders
    5. Obsessive-compulsive disorder
    6. Panic disorder
    7. Posttraumatic stress disorder
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
740 participants (actual)

Study arms

  • Experimental
    Brexpiprazole 1mg

    Tablets, Oral, 1mg once daily, 14 weeks Other Name: REXULTI

    Drug: Brexpiprazole

  • Experimental
    Brexpiprazole 2mg

    Tablets, Oral, 2 mg once daily, 14 weeks Other Name: REXULTI

    Drug: Brexpiprazole

  • Placebo comparator
    Placebo

    Tablets, Oral, once daily, 14 weeks

    Drug: Placebo

Interventions

  • Tablets, Oral, once daily, 14 weeks

    Also known as: REXULTI

  • DrugPlacebo

    Tablets, Oral, once daily, 14 weeks

06

What researchers measure

Primary outcomes

  1. Mean Changes From Baseline (Week 8 of the Antidepressant Treatment Period [Phase A]) in the MADRS Total Scores at Week 6 of the Double-blind Period (Phase B).

    The MADRS was a clinician-rated scale which evaluated the level of depression. The MADRS consisted of 10 items assessing apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thought. Each item was scored from 0 to 6, with higher scores indicating worse condition. Summed subscales were combined to compute a total score. Total score ranges from 0 to 60, with higher scores indicating worse condition.The mean changes were compared between antidepressant treatments and brexpiprazole as adjunctive therapy.

    Time frame: Baseline (the end of Phase A), at completion of administration (Week 6).

Secondary outcomes

  1. CGI-I Improvement Rate at Week 6 of the Double-blind Period (Phase B)

    Clinical Global Impression - Improvement (CGI-I) improvement rate: the proportion of participants who score 1 or 2 on the CGI-I scale at Week 6 of the double-blind period (Phase B). The CGI-I Scale was a clinician-rated scale which assessed the total improvement of the participant's condition compared to that at baseline. Scores range from 0 to 7:0 = Not assessed, 1= Very much improved, 2 = Much improved, 3= Minimally improved, 4= No change, 5= Minimally worse, 6= Much worse, 7= Very much worse. Higher scores indicated worse condition.

    Time frame: Baseline (the end of Phase A), at completion of administration (Week 6).

07

Results

Posted Aug 9, 2024

Participant flow

This trial was conducted in 740 participants from 145 trial sites in Japan.

Participant flow — Overall Study
MilestoneBrexpiprazole 1 mgBrexpiprazole 2 mgPlacebo
Started250246244
Completed238219232
Not completed122712
Withdrew: Adverse event3183
Withdrew: Physician decision102
Withdrew: Protocol violation385
Withdrew: Withdrawal by subject511
Withdrew: Protocol violation001

Outcome measures

PrimaryMean Changes From Baseline (Week 8 of the Antidepressant Treatment Period [Phase A]) in the MADRS Total Scores at Week 6 of the Double-blind Period (Phase B).

The MADRS was a clinician-rated scale which evaluated the level of depression. The MADRS consisted of 10 items assessing apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thought. Each item was scored from 0 to 6, with higher scores indicating worse condition. Summed subscales were combined to compute a total score. Total score ranges from 0 to 60, with higher scores indicating worse condition.The mean changes were compared between antidepressant treatments and brexpiprazole as adjunctive therapy.

Time frame:
Baseline (the end of Phase A), at completion of administration (Week 6).
Reported as:
Mean · Units on a scale
Mean Changes From Baseline (Week 8 of the Antidepressant Treatment Period [Phase A]) in the MADRS Total Scores at Week 6 of the Double-blind Period (Phase B).
Units on a scaleBrexpiprazole 1 mgBrexpiprazole 2 mgPlacebo
Mean Changes From Baseline (Week 8 of the Antidepressant Treatment Period [Phase A]) in the MADRS Total Scores at Week 6 of the Double-blind Period (Phase B).-8.5 ± 0.47-8.2 ± 0.47-6.7 ± 0.47
Statistical analysis
  • Brexpiprazole 2 mg vs Placebo · MMRM · p = 0.0312 · Mean difference (final values): -1.4 · 95% CI -2.7 to -0.1
  • Brexpiprazole 1 mg vs Placebo · MMRM · p = 0.0089 · Mean difference (final values): -1.7 · 95% CI -3.0 to -0.4
SecondaryCGI-I Improvement Rate at Week 6 of the Double-blind Period (Phase B)

Clinical Global Impression - Improvement (CGI-I) improvement rate: the proportion of participants who score 1 or 2 on the CGI-I scale at Week 6 of the double-blind period (Phase B). The CGI-I Scale was a clinician-rated scale which assessed the total improvement of the participant's condition compared to that at baseline. Scores range from 0 to 7:0 = Not assessed, 1= Very much improved, 2 = Much improved, 3= Minimally improved, 4= No change, 5= Minimally worse, 6= Much worse, 7= Very much worse. Higher scores indicated worse condition.

Time frame:
Baseline (the end of Phase A), at completion of administration (Week 6).
Reported as:
Number · percentage of participants
CGI-I Improvement Rate at Week 6 of the Double-blind Period (Phase B)
percentage of participantsBrexpiprazole 1 mgBrexpiprazole 2 mgPlacebo
CGI-I Improvement Rate at Week 6 of the Double-blind Period (Phase B)35.135.129.6
Statistical analysis
  • Brexpiprazole 2 mg vs Placebo · Chi-squared · p = 0.1964 · Diff: 5.5 · 95% CI -2.8 to 13.8
  • Brexpiprazole 1 mg vs Placebo · Chi-squared · p = 0.1969 · Diff: 5.5 · 95% CI -2.8 to 13.7

Adverse events

Collected over Adverse events were monitored from signing of the informed consent form until post-treatment observation period for up to 30 days (±5 days) after the final day of study medication administration (end of trial date [final day of observation]).. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brexpiprazole 1 mg0/250 (0%)3/250 (1.2%)108/250 (43.2%)
Brexpiprazole 2 mg0/246 (0%)3/246 (1.2%)153/246 (62.2%)
Placebo0/244 (0%)2/244 (0.8%)92/244 (37.7%)
Most frequent serious events
Most frequent serious events
EventBrexpiprazole 1 mgBrexpiprazole 2 mgPlacebo
CellulitisInfections and infestations0/2500/2461/244
Subarachnoid haemorrhageNervous system disorders0/2500/2461/244
Alcoholic pancreatitisGastrointestinal disorders0/2501/2460/244
Extramammary Paget's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2501/2460/244
EpilepsyNervous system disorders0/2501/2460/244
AppendicitisInfections and infestations1/2500/2460/244
Intentional overdoseInjury, poisoning and procedural complications1/2500/2460/244
IIIrd nerve paralysisNervous system disorders1/2500/2460/244
Most frequent other events
Showing 10 of 27
Most frequent other events
EventBrexpiprazole 1 mgBrexpiprazole 2 mgPlacebo
AkathisiaNervous system disorders15/25060/2463/244
NasopharyngitisInfections and infestations20/25016/24624/244
Weight increasedInvestigations18/25019/2466/244
TremorNervous system disorders16/25012/2469/244
Blood prolactin increasedInvestigations6/25015/2466/244
HyperprolactinaemiaEndocrine disorders3/25013/2463/244
InsomniaPsychiatric disorders9/25012/2468/244
HeadacheNervous system disorders6/2503/24611/244
Extrapyramidal disorderNervous system disorders1/25011/2462/244
ConstipationGastrointestinal disorders5/2509/2465/244

Baseline characteristics

Full Analysis Set (FAS) which comprised subjects who, after randomization, had received at least 1 dose of the study medication in the double-blind period (Phase B), and from whose the Montgomery Åsberg Depression Rating Scale (MADRS) total scores had been obtained at baseline and at least 1 time point after initiation of the treatment.

Age, Categorical
Age, Categorical(Participants)Brexpiprazole 1 mgBrexpiprazole 2 mgPlaceboTotal
<=18 years0000
Between 18 and 65 years248245243736
>=65 years0000
Age, Continuous
Age, Continuous(years)Brexpiprazole 1 mgBrexpiprazole 2 mgPlaceboTotal
Mean40.9 ± 10.840.0 ± 10.739.8 ± 10.840.2 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)Brexpiprazole 1 mgBrexpiprazole 2 mgPlaceboTotal
Female116102105323
Male132143138413
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Brexpiprazole 1 mgBrexpiprazole 2 mgPlaceboTotal
Asian248245243736
Region of Enrollment
Region of Enrollment(participants)Brexpiprazole 1 mgBrexpiprazole 2 mgPlaceboTotal
Japan248245243736
08

Study locations

1 site
  • Nanko-kokorono clinic
    Fukushima, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Jun 2022, 46 months.

Results were first posted in Aug 2024, 2 years 2 months after primary completion.

Of 16 phase 2/3 interventional studies under Depressive Disorder, Major, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 56. This study's 46 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2018
First posted
Oct 5, 2018
StartActual
Jul 30, 2018
Primary completionActual
Jun 6, 2022
CompletionActual
Jul 4, 2022
Results first posted
Aug 9, 2024
Last update
Aug 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03697603
Responsible party
Sponsor
First posted
Oct 5, 2018
Start date
Jul 30, 2018
Primary completion
Jun 6, 2022
Completion
Jul 4, 2022
Results posted
Aug 9, 2024
Last update
Aug 9, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion